title: Outcome of intravitreal bevacizumab for idiopathic choroidal neovascularization in the Chinese population.
abstract: OBJECTIVE
  To assess the long-term visual and anatomical outcomes and safety of intravitreal injection of bevacizumab for idiopathic choroidal neovascularization (ICNV) in Chinese patients.
  
  
  METHODS
  Retrospective interventional case series.
  
  
  METHODS
  Seventy-seven eyes of 77 patients with ICNV.
  
  
  METHODS
  Patients were given intravitreal injection of bevacizumab (1.25 mg/0.05 mL) for ICNV between March 2006 and May 2008. Main outcome measures were changes in best-corrected visual acuity (BCVA), central foveal thickness, which was measured by optical coherence tomography, and fluorescein angiography findings.
  
  
  RESULTS
  Mean follow-up was 14.3 (SD 2.4, range 10-20) months. Mean BCVA improved from 0.66 (SD 0.36) logMAR at baseline to 0.25 (SD 0.28) logMAR at final follow-up (p < 0.001). Sixty-one patients (79%) gained BCVA of > or = 2 Snellen lines, and 1 eye (1%) lost BCVA of > or = 2 Snellen lines. Mean central foveal thickness decreased from 365 (SD 124) microm at baseline to 211 (SD 94) microm at final visit (p < 0.001). Sixty-two eyes (81%) needed reinjection. Both BCVA improvement and the change in central foveal thickness between the 1- time injection group and the multi-injections group were not statistically significant (p = 0.45 and p = 0.19, respectively). No significant ocular or systemic adverse effects were observed.
  
  
  CONCLUSIONS
  The long-term results suggest an encouraging efficacy and safety of intravitreal bevacizumab for ICNV in Chinese patients.
authors.affiliation: Department of Ophthalmology, People's Hospital, Peking University, Beijing, China.
authors.forename: Hui-Jun
authors.initials: HJ
authors.lastname: Qi
authors.forename: Xiao-Xin
authors.initials: XX
authors.lastname: Li
authors.forename: Yong
authors.initials: Y
authors.lastname: Tao
mesh_terms: D000293:Adolescent; D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D044466:Asian People / Q000208:ethnology; D000068258:Bevacizumab; D002681:China / Q000453:epidemiology; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000208:ethnology; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D019233:Retreatment; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014822:Vitreous Body; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab